Omnicell (NASDAQ:OMCL) & KORU Medical Systems (NASDAQ:KRMD) Head-To-Head Contrast

KORU Medical Systems (NASDAQ:KRMD) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

Analyst Recommendations

This is a summary of recent ratings and price targets for KORU Medical Systems and Omnicell, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KORU Medical Systems	1	0	4	0	2.60
Omnicell	1	1	7	0	2.67

KORU Medical Systems currently has a consensus price target of $7.00, indicating a potential upside of 105.88%. Omnicell has a consensus price target of $57.86, indicating a potential upside of 55.11%. Given KORU Medical Systems’ higher possible upside, equities research analysts clearly believe KORU Medical Systems is more favorable than Omnicell.

Profitability

This table compares KORU Medical Systems and Omnicell’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
KORU Medical Systems	-4.03%	-10.63%	-6.51%
Omnicell	3.13%	5.66%	3.57%

Risk & Volatility

KORU Medical Systems has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Insider and Institutional Ownership

58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares KORU Medical Systems and Omnicell”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KORU Medical Systems	$41.13 million	3.80	-$2.64 million	($0.04)	-85.00
Omnicell	$1.18 billion	1.43	$2.05 million	$0.84	44.40

Omnicell has higher revenue and earnings than KORU Medical Systems. KORU Medical Systems is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Summary

Omnicell beats KORU Medical Systems on 11 of the 14 factors compared between the two stocks.

About KORU Medical Systems

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

About Omnicell

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.